SMT201800056T1 - 2-azabicicli sostituiti e loro uso come modulatori del recettore di orexina - Google Patents

2-azabicicli sostituiti e loro uso come modulatori del recettore di orexina

Info

Publication number
SMT201800056T1
SMT201800056T1 SM20180056T SMT201800056T SMT201800056T1 SM T201800056 T1 SMT201800056 T1 SM T201800056T1 SM 20180056 T SM20180056 T SM 20180056T SM T201800056 T SMT201800056 T SM T201800056T SM T201800056 T1 SMT201800056 T1 SM T201800056T1
Authority
SM
San Marino
Prior art keywords
azabicycles
substituted
receptor modulators
orexin receptor
orexin
Prior art date
Application number
SM20180056T
Other languages
English (en)
Italian (it)
Inventor
Christine F Gelin
Terry P Lebold
Brock T Shireman
Jeannie M Ziff
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SMT201800056T1 publication Critical patent/SMT201800056T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SM20180056T 2013-03-13 2014-03-12 2-azabicicli sostituiti e loro uso come modulatori del recettore di orexina SMT201800056T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780378P 2013-03-13 2013-03-13
EP14717576.4A EP2970314B1 (en) 2013-03-13 2014-03-12 Substituted 2-azabicycles and their use as orexin receptor modulators
PCT/US2014/024293 WO2014165070A1 (en) 2013-03-13 2014-03-12 Substituted 2-azabicycles and their use as orexin receptor modulators

Publications (1)

Publication Number Publication Date
SMT201800056T1 true SMT201800056T1 (it) 2018-03-08

Family

ID=50487148

Family Applications (3)

Application Number Title Priority Date Filing Date
SM20180056T SMT201800056T1 (it) 2013-03-13 2014-03-12 2-azabicicli sostituiti e loro uso come modulatori del recettore di orexina
SM20230223T SMT202300223T1 (it) 2013-03-13 2014-03-12 2-azabicicli sostituiti e loro uso come modulatori del recettore di orexina
SM20190655T SMT201900655T1 (it) 2013-03-13 2014-03-12 2-azabicicli sostituiti e loro uso come modulatori del recettore di orexina

Family Applications After (2)

Application Number Title Priority Date Filing Date
SM20230223T SMT202300223T1 (it) 2013-03-13 2014-03-12 2-azabicicli sostituiti e loro uso come modulatori del recettore di orexina
SM20190655T SMT201900655T1 (it) 2013-03-13 2014-03-12 2-azabicicli sostituiti e loro uso come modulatori del recettore di orexina

Country Status (38)

Country Link
US (5) US8969352B2 (enExample)
EP (4) EP4272824A3 (enExample)
JP (1) JP6275815B2 (enExample)
KR (1) KR102209424B1 (enExample)
CN (3) CN108864093A (enExample)
AR (1) AR095423A1 (enExample)
AU (2) AU2014248680B2 (enExample)
BR (1) BR112015022294B1 (enExample)
CA (1) CA2904618C (enExample)
CL (1) CL2015002609A1 (enExample)
CR (2) CR20210523A (enExample)
CY (3) CY1120024T1 (enExample)
DK (2) DK2970314T3 (enExample)
EA (1) EA029276B1 (enExample)
ES (3) ES2950032T3 (enExample)
HR (3) HRP20230633T1 (enExample)
HU (3) HUE063608T2 (enExample)
IL (2) IL240466B (enExample)
JO (1) JOP20140092B1 (enExample)
LT (2) LT2970314T (enExample)
ME (2) ME03011B (enExample)
MX (2) MX361529B (enExample)
MY (1) MY183725A (enExample)
NI (1) NI201500130A (enExample)
NO (1) NO3107630T3 (enExample)
PE (1) PE20151599A1 (enExample)
PH (1) PH12015501929B1 (enExample)
PL (3) PL2970314T3 (enExample)
PT (2) PT3363438T (enExample)
RS (3) RS59466B1 (enExample)
SG (1) SG11201507415QA (enExample)
SI (2) SI3363438T1 (enExample)
SM (3) SMT201800056T1 (enExample)
TW (1) TWI621618B (enExample)
UA (1) UA118669C2 (enExample)
UY (1) UY35409A (enExample)
WO (1) WO2014165070A1 (enExample)
ZA (1) ZA201507562B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012004753A (es) 2009-10-23 2012-09-07 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina.
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
AU2012340200B2 (en) 2011-11-17 2017-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-Terminal Kinase (JNK)
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TWI621618B (zh) * 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
JP6262885B2 (ja) 2014-03-06 2018-01-17 シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドＳｈａｎｇｈａｉ Ｈａｉｙａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． オレキシン受容体拮抗剤としてのピペリジン誘導体
WO2016040789A1 (en) * 2014-09-11 2016-03-17 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
WO2016100157A2 (en) * 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
AU2016295693B2 (en) 2015-07-17 2020-05-21 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
WO2017028732A1 (zh) * 2015-08-14 2017-02-23 上海海雁医药科技有限公司 食欲素受体拮抗剂化合物的晶型及其制备方法和应用
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JP6936224B2 (ja) 2015-11-23 2021-09-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． オクタヒドロピロロ［３，４−ｃ］ピロール誘導体およびその使用
UA125873C2 (uk) 2016-03-10 2022-06-29 Янссен Фармацевтика Нв Спосіб лікування депресії з використанням антагоністів рецептора орексин-2
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
JP6678779B2 (ja) 2016-06-13 2020-04-08 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒ（ｎｒ１ｈ４）調節化合物
AU2017363307B2 (en) 2016-11-22 2021-07-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
PT4122464T (pt) 2017-03-28 2024-06-27 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças do fígado
GB2558975B (en) * 2017-09-01 2019-01-23 Chronos Therapeutics Ltd Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
JP7391012B2 (ja) 2017-09-01 2023-12-04 クロノス セラピューティクス リミテッド オレキシン受容体拮抗薬としての置換２－アザビシクロ［３．１．１］ヘプタンおよび２－アザビシクロ［３．２．１］オクタン誘導体
CA3099763A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
JP7642540B2 (ja) * 2018-12-14 2025-03-10 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ－ｊｕｎ－ｎ末キナーゼのピラゾロピリジンインヒビターおよびそれらの使用
CA3124422A1 (en) 2018-12-28 2020-07-02 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
SG11202107434PA (en) 2019-01-15 2021-08-30 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CN118388473A (zh) 2019-02-19 2024-07-26 吉利德科学公司 Fxr激动剂的固体形式

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674793A (en) 1967-03-29 1972-07-04 Sterling Drug Inc 6-hydroxy-2-azabicyclo(2.2.2)octan-3-ones and 2-azabicyclo(2.2.2.)octane-3,6-diones
US6505492B2 (en) 2001-04-11 2003-01-14 Bethlehem Steel Corporation Method and apparatus for forming deep-drawn articles
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
WO2004069816A1 (en) 2003-02-07 2004-08-19 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
CA2516329A1 (en) 2003-02-21 2004-09-02 Pharmacia & Upjohn Company Llc Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate, intermediates, and process to prepare and isolate them
BRPI0620066A2 (pt) 2005-12-20 2011-11-01 Novartis Ag derivados de ácido nicotìnico como moduladores do receptor de glutamato metabotrópico, processo para preparação dos mesmos, composição farmacêutica e uso dos referidos derivados
CA2663113A1 (en) 2006-09-11 2008-03-20 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutanate receptors
ES2357992T3 (es) 2006-12-01 2011-05-04 Actelion Pharmaceuticals Ltd. Derivados de 3-heteroaril(amino o amido)-1-(bifenil o feniltiazolil)carbonilpiperidina como inhibidores del receptor de orexina.
AR064561A1 (es) 2006-12-28 2009-04-08 Actelion Pharmaceuticals Ltd Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
WO2008150364A1 (en) * 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
AU2008276055B2 (en) 2007-07-17 2013-01-31 Bristol-Myers Squibb Company Pyridone GPR119 G protein-coupled receptor agonists
KR101204213B1 (ko) 2007-12-21 2012-11-26 에프. 호프만-라 로슈 아게 오렉신 수용체 길항제로서의 헤테로아릴 유도체
NZ588080A (en) * 2008-02-21 2012-04-27 Actelion Pharmaceuticals Ltd 2-Aza-bicyclo[2.2.1]heptane derivatives
EP2318367B1 (en) 2008-04-30 2013-03-20 Actelion Pharmaceuticals Ltd. Piperidine and pyrrolidine compounds
MX2011000664A (es) 2008-07-16 2011-02-24 Schering Corp Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119.
EP2349269A4 (en) 2008-10-21 2012-04-25 Merck Sharp & Dohme 2,5-DISUBSTITUTED PIPERIDINOREXINE RECEPTOR ANTAGONISTS
JP2012506378A (ja) 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション ２，３−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト
AU2009324239A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
CN102459229A (zh) 2009-04-24 2012-05-16 葛兰素集团有限公司 用作食欲肽拮抗剂的3-氮杂二环[4.1.0]庚烷
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
MX2012004753A (es) 2009-10-23 2012-09-07 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina.
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
WO2011053688A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
WO2011066137A1 (en) 2009-11-24 2011-06-03 Schering Corporation Substituted biaryl derivatives and methods of use thereof
JP2013513664A (ja) 2009-12-14 2013-04-22 インスパイアー ファーマシューティカルズ，インコーポレイティド 架橋二環式ｒｈｏキナーゼ阻害化合物、組成および使用
WO2011087812A1 (en) 2009-12-21 2011-07-21 Vanderbilt University Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective m1 agonists and methods of making and using same
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US20130096141A1 (en) 2010-06-18 2013-04-18 Bernard R. Neustadt Bicyclic heterocycle derivatives and methods of use thereof
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
EP2911675A4 (en) 2012-10-23 2016-06-01 Merck Sharp & Dohme 2-PYRIDYLOXY-3-SUBSTITUTED 4-NITRIL-OREXINE RECEPTOR ANTAGONISTS
AU2013347538B2 (en) 2012-11-16 2017-04-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
JP6532474B2 (ja) 2014-02-06 2019-06-19 アッヴィ・インコーポレイテッド ６−ヘテロアリールオキシ−および６−アリールオキシ−キノリン−２−カルボキシアミドならびにその使用
WO2016040789A1 (en) 2014-09-11 2016-03-17 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators

Also Published As

Publication number Publication date
US9845333B2 (en) 2017-12-19
CA2904618C (en) 2021-12-07
PE20151599A1 (es) 2015-11-12
US20160052939A1 (en) 2016-02-25
DK2970314T3 (en) 2018-02-26
CY1126106T1 (el) 2023-11-15
ME03572B (me) 2020-07-20
CN110669052B (zh) 2022-10-11
EP4272824A3 (en) 2024-01-10
MY183725A (en) 2021-03-10
LT3363438T (lt) 2019-11-11
EP3363438B1 (en) 2019-09-18
SMT201900655T1 (it) 2020-01-14
HK1219725A1 (en) 2017-04-13
DK3363438T3 (da) 2019-11-11
EA029276B1 (ru) 2018-03-30
US10183953B2 (en) 2019-01-22
CL2015002609A1 (es) 2016-03-28
HUE063608T2 (hu) 2024-01-28
US9611277B2 (en) 2017-04-04
IL240466B (en) 2019-03-31
BR112015022294B1 (pt) 2022-09-13
HRP20180303T1 (hr) 2018-03-23
RS56875B1 (sr) 2018-04-30
EP4272824A2 (en) 2023-11-08
SMT202300223T1 (it) 2023-09-06
CY1122392T1 (el) 2021-01-27
CR20150433A (es) 2015-10-26
CR20210523A (es) 2021-11-19
NI201500130A (es) 2015-11-30
KR20150126694A (ko) 2015-11-12
SG11201507415QA (en) 2015-10-29
IL264606A (en) 2019-02-28
LT2970314T (lt) 2018-02-12
PL3622956T3 (pl) 2023-09-18
RS59466B1 (sr) 2019-11-29
CN110669052A (zh) 2020-01-10
NO3107630T3 (enExample) 2018-01-06
CY1120024T1 (el) 2018-12-12
SI3363438T1 (sl) 2019-11-29
US20150174129A1 (en) 2015-06-25
PH12015501929A1 (en) 2016-01-04
RS64551B9 (sr) 2023-12-29
AU2018204835B2 (en) 2019-08-08
RS64551B1 (sr) 2023-10-31
AU2014248680A1 (en) 2015-08-27
EP3622956A1 (en) 2020-03-18
TWI621618B (zh) 2018-04-21
SI2970314T1 (en) 2018-02-28
PH12015501929B1 (en) 2016-01-04
CN108864093A (zh) 2018-11-23
HRP20192032T1 (hr) 2020-02-07
EP3622956B1 (en) 2023-06-07
EP3622956B9 (en) 2023-09-27
UY35409A (es) 2014-09-30
MX368466B (es) 2019-10-03
PL2970314T3 (pl) 2018-05-30
EP2970314B1 (en) 2017-12-13
US20170204096A1 (en) 2017-07-20
EP3363438A1 (en) 2018-08-22
US8969352B2 (en) 2015-03-03
NZ710872A (en) 2020-10-30
EP3622956C0 (en) 2023-06-07
MX361529B (es) 2018-12-07
US9447117B2 (en) 2016-09-20
CN105308048B (zh) 2019-10-08
KR102209424B1 (ko) 2021-01-29
PT3363438T (pt) 2019-12-11
EA201591703A1 (ru) 2016-02-29
EP2970314A1 (en) 2016-01-20
PL3363438T3 (pl) 2020-02-28
AR095423A1 (es) 2015-10-14
HUE047592T2 (hu) 2020-05-28
BR112015022294A2 (pt) 2017-07-18
WO2014165070A1 (en) 2014-10-09
PT2970314T (pt) 2018-03-05
ES2760564T3 (es) 2020-05-14
AU2014248680B2 (en) 2018-07-26
JP2016512535A (ja) 2016-04-28
HUE036193T2 (hu) 2018-06-28
US20170015651A1 (en) 2017-01-19
CN105308048A (zh) 2016-02-03
MX2015011815A (es) 2016-11-07
ES2950032T3 (es) 2023-10-04
AU2018204835A1 (en) 2018-07-19
ES2659397T3 (es) 2018-03-15
CA2904618A1 (en) 2014-10-09
JP6275815B2 (ja) 2018-02-07
US20140275118A1 (en) 2014-09-18
TW201446757A (zh) 2014-12-16
JOP20140092B1 (ar) 2021-08-17
HRP20230633T1 (hr) 2023-09-29
UA118669C2 (uk) 2019-02-25
ME03011B (me) 2018-10-20
ZA201507562B (en) 2019-04-24
IL240466A0 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
IL264606A (en) 2- Converted azabicycles and their use as orexin receptor modulators
IL240929B (en) 7- Converted azabicycles and their use as orexin receptor modulators
IL245733A0 (en) aplnr modulators and their uses
IL240166A0 (en) spiro-lactam modulators of the NMDA receptor and their uses
IL240164A0 (en) spiro-lactam modulators of the NMDA receptor and their uses
IL240163B (en) spiro-lactam modulators of the NMDA receptor and their uses
IL240162A0 (en) spiro-lactam modulators of the NMDA receptor and their uses
IL240165A0 (en) spiro-lactam modulators of the NMDA receptor and their uses
ZA201800827B (en) Substituted 4-azaindoles and their use as glun2b receptor modulators
GB201305277D0 (en) Novel combination and use
ZA201405392B (en) Substituted phenylimidazopyrazoles and use thereof
GB201307989D0 (en) Novel combinations and use
EP3013851A4 (en) MODULATORS OF BRADYKININ RECEPTORS AND THEIR USE